ATE388162T1 - Verfahren zur beseitigung von viren - Google Patents

Verfahren zur beseitigung von viren

Info

Publication number
ATE388162T1
ATE388162T1 AT98953439T AT98953439T ATE388162T1 AT E388162 T1 ATE388162 T1 AT E388162T1 AT 98953439 T AT98953439 T AT 98953439T AT 98953439 T AT98953439 T AT 98953439T AT E388162 T1 ATE388162 T1 AT E388162T1
Authority
AT
Austria
Prior art keywords
methods
immunoglobulin
excipient
viruses
elimination
Prior art date
Application number
AT98953439T
Other languages
English (en)
Inventor
Holten Robert Van
George E Oulundsen
Original Assignee
Ortho Clinical Diagnostics Inc
Millipore Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Clinical Diagnostics Inc, Millipore Corp filed Critical Ortho Clinical Diagnostics Inc
Application granted granted Critical
Publication of ATE388162T1 publication Critical patent/ATE388162T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/022—Filtration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/88—Manufacture, treatment, or detection of nanostructure with arrangement, process, or apparatus for testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Glass Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Separation By Low-Temperature Treatments (AREA)
  • External Artificial Organs (AREA)
  • Piles And Underground Anchors (AREA)
AT98953439T 1997-10-14 1998-10-14 Verfahren zur beseitigung von viren ATE388162T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/950,157 US6096872A (en) 1997-10-14 1997-10-14 Viral clearance process

Publications (1)

Publication Number Publication Date
ATE388162T1 true ATE388162T1 (de) 2008-03-15

Family

ID=25490036

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98953439T ATE388162T1 (de) 1997-10-14 1998-10-14 Verfahren zur beseitigung von viren

Country Status (12)

Country Link
US (1) US6096872A (de)
EP (1) EP1030862B1 (de)
JP (1) JP4255210B2 (de)
KR (1) KR100547077B1 (de)
CN (2) CN1576281B (de)
AT (1) ATE388162T1 (de)
AU (1) AU744845B2 (de)
CA (1) CA2306181C (de)
DE (1) DE69839218T2 (de)
ES (1) ES2302361T3 (de)
NO (1) NO326392B1 (de)
WO (1) WO1999019343A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020063597A (ko) * 1999-12-20 2002-08-03 미츠비시 웰파마 가부시키가이샤 다공성막으로 처리되어 바이러스가 제거된 혈장 단백질조성물 및 그 제조 방법
JP4340062B2 (ja) * 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6365395B1 (en) * 2000-11-03 2002-04-02 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
AU784808B2 (en) * 2001-04-02 2006-06-29 Kedrion Melville Inc. Prion and viral clearance process
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
US6893639B2 (en) * 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
KR100451308B1 (ko) * 2001-12-28 2004-10-06 선바이오(주) 단백질 의약품 정제 방법에서의 바이러스 제거 방법
US7118675B2 (en) * 2002-02-04 2006-10-10 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
DE10211632A1 (de) * 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
CA2487072A1 (en) 2002-05-23 2003-12-04 Ortho-Clinical Diagnostics, Inc. Capture, concentration and quantitation of abnormal prion protein from biological fluids using depth filtration
CA2489123C (en) * 2002-06-14 2011-03-15 Centocor, Inc. Use of a clathrate modifier to promote passage of proteins during nanofiltration
ES2626268T3 (es) * 2002-09-11 2017-07-24 Chugai Seiyaku Kabushiki Kaisha Método de purificación de proteínas
US20040116676A1 (en) * 2002-09-30 2004-06-17 Hotta Joann Methods for removal of contaminants from blood product solutions
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
ES2290553T3 (es) * 2003-05-19 2008-02-16 Millipore Corporation Procedimiento para prefiltrar una solucion de proteinas.
AU2005229674B2 (en) 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
US20060270015A1 (en) * 2005-05-26 2006-11-30 Dan Pawlak Thrombin purification
ES2775974T3 (es) * 2006-06-26 2020-07-28 Omrix Biopharmaceuticals Inc Eliminación de virus por nanofiltración
EP2043767B1 (de) 2006-07-14 2020-03-25 Wisconsin Alumni Research Foundation Adsorptionsmembranen zum einfangen von viren
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
PT2271382E (pt) * 2008-04-15 2013-05-07 Grifols Therapeutics Inc Ultrafiltração em dois andares/diafiltração
BRPI1006519A2 (pt) * 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
WO2010132288A1 (en) * 2009-05-11 2010-11-18 Millipore Corporation Method for scaling mixing operations
AU2011343813B2 (en) 2010-12-15 2015-05-21 Takeda Pharmaceutical Company Limited Eluate collection using conductivity gradient
KR20120098202A (ko) * 2011-02-28 2012-09-05 (주)차바이오앤디오스텍 자하거 추출물 및 자하거 추출물 제조 방법
BR112013024521A2 (pt) * 2011-03-25 2019-09-24 Genentech Inc métodos de purificação de proteínas
KR101993488B1 (ko) 2011-09-01 2019-06-26 추가이 세이야쿠 가부시키가이샤 한외여과에 의해 고도로 농축된 항체를 포함하는 조성물의 제조 방법
CN102599332B (zh) * 2012-03-09 2014-07-30 上海杰隆生物制品股份有限公司 一种利用禽血生产低灰分禽血浆蛋白粉的方法
EP2934603A1 (de) * 2012-12-20 2015-10-28 Omrix Biopharmaceuticals Ltd. Inaktivierte virale biologische mischung
WO2015140751A1 (en) * 2014-03-21 2015-09-24 Boreal Invest Terminal nanofiltration of solubilized protein compositions for removal of immunogenic aggregates
JP6661547B2 (ja) * 2014-05-13 2020-03-11 アムジエン・インコーポレーテツド フィルタ及び濾過プロセスで用いるためのプロセス制御システム及び方法
CA3159833A1 (en) 2014-05-21 2015-11-26 Unchained Labs Systems and methods for exchange of buffer solutions
AU2017269839A1 (en) 2016-05-27 2018-11-22 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
US20190167823A1 (en) * 2016-08-09 2019-06-06 Asahi Kasei Medical Co., Ltd. Method for treating solution contaminated with porcine circoviruses
EP3700928A1 (de) 2017-10-26 2020-09-02 Alexion Pharmaceuticals, Inc. Dosierung und verabreichung von anti-c5-antikörpern zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh) und atypischem hämolytisch-urämischem syndrom (ahus)
EP3814373A1 (de) 2018-06-28 2021-05-05 Alexion Pharmaceuticals, Inc. Verfahren zur herstellung von anti-c5 -antikörpern
EP3636657A1 (de) * 2018-10-08 2020-04-15 Ablynx N.V. Chromatographiefreies antikörperreinigungsverfahren
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下（sc）施用抗c5抗体治疗补体相关病症
CN116297915B (zh) * 2023-02-10 2023-12-01 中国食品药品检定研究院 聚山梨酯类辅料的分析鉴定方法
FR3157849A1 (fr) * 2023-12-27 2025-07-04 Technip Energies France Méthode d’installation d’un dispositif d’ancrage sur fond marin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3449314A (en) * 1966-06-03 1969-06-10 Ortho Pharma Corp Preparation of anti-rh globulin from human plasma
US3916026A (en) * 1968-09-19 1975-10-28 Biotest Serum Institut Gmbh Method for the preparation of gamma-globulin suitable for intravenous use
US4021540A (en) * 1975-07-28 1977-05-03 Ortho Diagnostics Inc. Preparation of a hepatitis B immune globulin and use thereof as a prophylactic material
DE2624373C2 (de) * 1976-05-31 1983-02-03 Arnold Dr. 8782 Karlstadt Seufert Verfahren zur Herstellung von steril filtriertem Kryopräzipilat mit einer Anreicherung des Faktors VIII
US4590002A (en) * 1984-12-10 1986-05-20 Ortho Diagnostic Systems, Inc. Methods for preparation of highly purified, gamma globulins free of hepatitis-B-virus infectivity
DE3641115A1 (de) * 1986-12-02 1988-06-16 Lentia Gmbh Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins
US5115101A (en) * 1988-06-08 1992-05-19 Miles Inc. Removal of protein A from antibody preparations
FR2639645B1 (fr) * 1988-11-25 1992-05-29 Elf Aquitaine Solutions liquides concentrees de polysaccharides
DE4137996A1 (de) * 1991-11-19 1993-05-27 Behringwerke Ag Verfahren zur herstellung eines virussicheren thrombinkonzentrates
SE9500724D0 (sv) * 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
FR2724182B1 (fr) * 1994-09-02 1996-12-13 Pasteur Institut Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations
EP2095873A1 (de) * 1996-08-30 2009-09-02 Upfront Chromatography A/S Isolierung von Immunglobulinen

Also Published As

Publication number Publication date
JP4255210B2 (ja) 2009-04-15
DE69839218T2 (de) 2009-03-19
EP1030862A4 (de) 2002-10-23
WO1999019343A1 (en) 1999-04-22
NO20001949D0 (no) 2000-04-13
KR20010015753A (ko) 2001-02-26
CA2306181A1 (en) 1999-04-22
CN1576281B (zh) 2012-08-08
ES2302361T3 (es) 2008-07-01
JP2002500164A (ja) 2002-01-08
CN1279688A (zh) 2001-01-10
CN1576281A (zh) 2005-02-09
DE69839218D1 (de) 2008-04-17
NO20001949L (no) 2000-06-14
NO326392B1 (no) 2008-11-24
EP1030862A1 (de) 2000-08-30
EP1030862B1 (de) 2008-03-05
CA2306181C (en) 2010-09-21
KR100547077B1 (ko) 2006-02-01
AU1081799A (en) 1999-05-03
AU744845B2 (en) 2002-03-07
US6096872A (en) 2000-08-01
CN1163503C (zh) 2004-08-25

Similar Documents

Publication Publication Date Title
DE69839218D1 (de) Verfahren zur beseitigung von viren
ATE170630T1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
ATE432948T1 (de) Verfahren zur beseitigung von viren und prionen aus immunglobulinzusammensetzungen
DE69632224D1 (de) Reduzierung von Gelation von Fettsäureacylierten Proteinen unter Nutzung von Zitratpuffer
CA2290485A1 (en) Method for the production of non-immunogenic proteins
ATE200679T1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
ATE123780T1 (de) Verfahren zur verwendung und herstellung von peptiden.
NO177188C (no) Fremgangsmåte for separering av humane eller animalske plasmaproteiner
DE59003771D1 (de) Verfahren zur Herstellung von cyclischen Aminosäurederivaten sowie Zwischenprodukte.
ATE68826T1 (de) Verfahren zur herstellung von reifem, menschlichem serum-albumin.
ATE154200T1 (de) Verfahren zur gewinnung von alpha-lactalbumin und beta-lactoglobulin aus einem molkeproteinprodukt
DE3768833D1 (de) Verfahren zur herstellung von hcmv-glykoproteinen, antikoerper dagegen und hcmv-vakzine und dazu zu verwendende rekombinante vektoren.
DK322188D0 (da) Fremgangsmaade til fremstilling af protein
ATE279441T1 (de) Verfahren zur herstellung von genetisch veränderten lymphozyten vorläuferzellen von wirbeltieren und deren gebrauch zur produktion von heterologen bindeproteinen
BR9709569B1 (pt) processo para ativação de proteìna desnaturada.
ATE30844T1 (de) Verfahren zur herstellung der wichtigsten proteine des haemolysierten bluts in einer nichtdenaturierten form.
AT379510B (de) Verfahren zur herstellung einer faktor viii (ahf) -haeltigen praeparation
DE69434221D1 (de) Bindungs domänen von plasmodium vivax und plasmodium falciparum erythrozyten-bindenden proteinen
ATE166881T1 (de) Verfahren zur herstellung von faktor viii
DE3769096D1 (de) Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion.
ATE212360T1 (de) Polyethylenglycol-hirudin-konjugate, deren verfahren zur herstellung und verwendung für die heilung von thrombosen
ATE118982T1 (de) Verfahren zur herstellung von transparenten milchmolkeproteinen und milchmolkeproteinprodukte.
DE59310073D1 (de) Verfahren zur Inaktivierung von Viren in Präparationen von Proteinen
ATE250132T1 (de) Verfahren zur extraktion von periplasmatischen proteinen aus prokaryotischen mikroorganismen in der anwesenheit von arginin
DE3687995D1 (de) Verfahren zur reinigung von interferon und so hergestellte zusammensetzung.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties